OncoMatch

OncoMatch/Clinical Trials/NCT05963074

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Is NCT05963074 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ibrutinib and Venetoclax for leukemia, lymphocytic, chronic, b-cell.

Phase 2RecruitingJanssen Research & Development, LLCNCT05963074Data as of May 2026

Treatment: Ibrutinib · Venetoclax — The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

Check if I qualify

Extracted eligibility criteria

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • The Oncology Institute Clinical Research · Cerritos, California
  • Cancer and Blood Specialty Clinic · Los Alamitos, California
  • SLO Oncology and Hematology Health Center · San Luis Obispo, California
  • Providence Medical Foundation · Santa Rosa, California
  • PIH Health Hospital · Whittier, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify